Anti-CEA-CAR-T Cells therapy(First Song Biotechnology)

N/A

Report date: 2024/10/30 17:12:33

Base Information

Drug NameAnti-CEA-CAR-T Cells therapy(First Song Biotechnology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CEA
TargetsCarcinoembryonic antigen
Therapy Area/IndicationsCarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChina Medical University, ChinaShanghai First Song Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai First Song Therapeutics Co LtdChina Medical University, China
Inactive CompaniesN/A
Active IndicationsCarcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A